Trial Profile
A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 14 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2013 Planned end date changed from 1 Feb 2015 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.